MAIA Biotechnology, Inc. financial data

Symbol
MAIA on NYSE
Industry
Pharmaceutical Preparations
Location
444 West Lake Street, Suite 1700, Chicago, IL
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 21, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 253 % +26.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.6M shares +47.9%
Common Stock, Shares, Outstanding 26.2M shares +54%
Entity Public Float 67.5M USD +200%
Common Stock, Value, Issued 2.62K USD +54%
Weighted Average Number of Shares Outstanding, Basic 22.2M shares +67.4%
Weighted Average Number of Shares Outstanding, Diluted 22.2M shares +67.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 10M USD -9.93%
General and Administrative Expense 6.95M USD -23.4%
Operating Income (Loss) -17M USD +16%
Income Tax Expense (Benefit) 0 USD
Earnings Per Share, Basic -1.05 USD/shares +29.5%
Earnings Per Share, Diluted -1.05 USD/shares +29.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 0 USD
Assets, Current 10.2M USD +34.2%
Other Assets, Noncurrent 2.8K USD 0%
Assets 10.2M USD +34.2%
Accounts Payable, Current 1.51M USD -7.7%
Accrued Liabilities, Current 2.32M USD -29.7%
Liabilities, Current 3.83M USD -22.4%
Liabilities 6.52M USD -8.02%
Accumulated Other Comprehensive Income (Loss), Net of Tax -30.6K USD -88.3%
Retained Earnings (Accumulated Deficit) -87.2M USD -36.3%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 3.63M USD +661%
Liabilities and Equity 10.2M USD +34.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.59M USD -6.73%
Net Cash Provided by (Used in) Financing Activities 4.72M USD
Common Stock, Shares Authorized 70M shares 0%
Common Stock, Shares, Issued 26.2M shares +54%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.12M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.6M USD +34.3%
Deferred Tax Assets, Valuation Allowance 15.2M USD +46.4%
Deferred Tax Assets, Gross 15.2M USD +46.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -23.3M USD -17.7%
Deferred Tax Assets, Operating Loss Carryforwards 8.24M USD +57.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Additional Paid in Capital 90.9M USD +41%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.91M USD -38.1%
Interest Expense 85 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%